Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Appolinaire A. Olou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6754-2969; OpenAlex author ID A5057693072. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 7

  1. Comprehensive genome sequencing associates elevated mitochondrial DNA and homoplasmy with early stage I of pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.115453↗
  2. EV DNA from pancreatic cancer patient-derived cells harbors molecular, coding, non-coding signatures and mutational hotspots. Co-author DOI 10.1038/s42003-025-07567-1↗
  3. Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancreatic cancer. Co-author DOI 10.1136/jitc-2024-010057↗
  4. Combined Omipalisib and MAPK Inhibition Suppress PDAC Growth. Co-author DOI 10.3390/cancers17071152↗
  5. SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1. Co-author DOI 10.1007/s12079-022-00691-1↗
  6. Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. First author DOI 10.1038/s41419-022-04572-8↗
  7. Correction: Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. First author DOI 10.1038/s41419-022-04615-0↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bailey A. Bye · 5 shared papers, 2022–2025 · strength 0.98
  2. Michael Nathan VanSaun · 5 shared papers, 2022–2025 · strength 0.98
  3. R. McKinnon Walsh · 4 shared papers, 2022–2025 · strength 0.80
  4. M. Rohan Fernando · 2 shared papers, 2025–2026 · strength 0.75
  5. Mariana T. Ruckert · 4 shared papers, 2022–2025 · strength 0.71
  6. Sharon Manley · 2 shared papers, 2022 · strength 0.29
  7. Shrikant Anant · 2 shared papers, 2022 · strength 0.29
  8. Danny R. Welch · 1 shared paper, 2025 · strength 0.25
  9. Prasad R. Dandawate · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.